Solid tablet dosage form of ristrizole
The present invention relates to a solid tablet oral dosage form of: 2, 2 '-bis (pyridin-4-yl)-1H, 1' H-5, 5 '-bibenzo [d] imidazole (which may also be referred to as 2, 2'-di-4-pyridinyl-6, 6 '-1H-benzimidazole; 2, 5, 5 '-bis [2-(4-pyridyl)-1H-benzimidazole]; 2, 2 '-bis (4-pyridyl)-3H, 3' H-5, 5 '-biphenyl imidazole is taken as a raw material; or a 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole), which is referenced herein in the form of an INN name ristrizole, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof; and pharmaceutically acceptable derivatives, salts, hydrates, solvates, complexes, bioisosteres, metabolites or prodrugs thereof..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 22. Sept. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WILSON FRANCIS X [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-09-22, Last update posted on www.tib.eu: 2024-01-22, Last updated: 2024-01-26 |
|---|
| Patentnummer: |
CN116801867 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018239234 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018239234 | ||
| 003 | DE-627 | ||
| 005 | 20240126103527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231013s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018239234 | ||
| 035 | |a (EPA)CN116801867 | ||
| 035 | |a (EPA)74679044 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WILSON FRANCIS X |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Solid tablet dosage form of ristrizole |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-09-22, Last update posted on www.tib.eu: 2024-01-22, Last updated: 2024-01-26 | ||
| 520 | |a The present invention relates to a solid tablet oral dosage form of: 2, 2 '-bis (pyridin-4-yl)-1H, 1' H-5, 5 '-bibenzo [d] imidazole (which may also be referred to as 2, 2'-di-4-pyridinyl-6, 6 '-1H-benzimidazole; 2, 5, 5 '-bis [2-(4-pyridyl)-1H-benzimidazole]; 2, 2 '-bis (4-pyridyl)-3H, 3' H-5, 5 '-biphenyl imidazole is taken as a raw material; or a 2-pyridin-4-yl-6-(2-pyridin-4-yl-3H-benzimidazol-5-yl)-1H-benzimidazole), which is referenced herein in the form of an INN name ristrizole, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof; and pharmaceutically acceptable derivatives, salts, hydrates, solvates, complexes, bioisosteres, metabolites or prodrugs thereof. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a TRESPIDI LORENZO |4 aut | |
| 700 | 0 | |a CARNIAUX JEAN-FRANCOIS |4 aut | |
| 700 | 0 | |a TIMMINS PETER |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 22. Sept. |
| 773 | 1 | 8 | |g year:2023 |g day:22 |g month:09 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/74679044/publication/CN116801867A1?q=CN116801867 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 22 |c 09 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 22 |c 09 | ||